Search results
30 mar 2022 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
We enrolled 654 patients in the BRAVE-AA1 trial and 546 in...
- Images in Clinical Medicine Primary Cutaneous Blastomycosis A. Alhatem and K.C. Smith
A 53-year-old landscaper presented with a 4-month history of...
- Perspective Real-World Evidence — Where Are We Now J. Concato and J. Corrigan-Curay
Notwithstanding ongoing confusion over the concepts of...
- Clinical Practice Nonspecific Low Back Pain A. Chiarotto and B.W. Koes
Nonspecific low back pain is diagnosed by ruling out other...
- Editorial Baricitinib in Alopecia Areata A. Messenger and M. Harries
Scalp hair regrowth is associated with improvements in...
- Clinical Problem-Solving Looking Back L. Glick and Others
On examination, the temperature was 36.1°C, the blood...
- Correspondence Dec 15, 2022 Ivermectin Treatment for Covid-19
Reis et al. (May 5 issue) 1 present the results of the...
- Editorial Audio Interview
In this audio interview conducted on May 2, 2022, the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
14 gru 2022 · Reis et al. (May 5 issue) 1 present the results of the TOGETHER platform trial, a large trial of ivermectin in outpatients with Covid-19.
We included randomized controlled trials that evaluated patients with confirmed COVID-19, or those with suspicion of COVID-19 by clinical symptoms and imaging findings, which compared systemic ivermectin with placebo, no treatment, standard care (as defined by the researchers in the individual studies) or other drugs for COVID-19 treatment ...
13 maj 2021 · BENGALURU, May 13 (Reuters) - At least two Indian states have said they plan to dose their populations with the anti-parasitic drug ivermectin to protect against severe COVID-19 infections...
13 cze 2022 · Among 19 randomized trials included; 10 studies concluded that ivermectin may have a possible effect in treating COVID-19. To address the conflicts and clear up the gray area; we precisely assessed the risk of bias of studies using the Cochrane risk-of-bias tool for randomized trials.
This trial was conducted to test the efficacy of ivermectin in mild and moderate coronavirus disease 19 (COVID-19). Methods: A double blind, parallel, randomised, placebo-controlled trial conducted among adult COVID-19 patients with mild to moderate disease severity on admission in a COVID dedicated tertiary healthcare of eastern India.
We found 14 studies with 1678 participants that investigated ivermectin compared to no treatment, placebo, or usual care. For treatment, there were nine studies of people with moderate COVID-19 in hospital and four of outpatients with mild COVID-19.
